Table 3 Multivariate analysis of outcome variables.

From: Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

  

OS

LFS

RI

NRM

GRFS

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

HR (95%CI)

p value

Conditioning

FluMel

1

 

1

 

1

 

1

 

1

 

FBM/FTM

0.7 (0.52–0.94)

0.02

0.78 (0.61–0.99)

0.04

1.09 (0.78–1.52)

0.62

0.56 (0.36–0.86)

0.009

0.99 (0.8–1.22)

0.94

Year at allo-HCT (by 3 years)

0.89 (0.81– 0.99)

0.04

0.93 (0.85–1.03)

0.15

0.88 (0.78–1)

0.06

0.98 (0.85–1.14)

0.76

0.96 (0.88–1.05)

0.4

Age at allo-HCT (per 10 years)

1.19 (1.05–1.35)

0.006

1.09 (0.98–1.23)

0.12

0.89 (0.78–1.03)

0.12

1.46 (1.21–1.76)

<0.001

1.11 (0.99–1.23)

0.06

Female to Male donor

No

1

 

1

 

1

 

1

 

1

 

Yes

1.27 (0.98–1.65)

0.06

1.27 (1–1.61)

0.053

1.23 (0.88–1.71)

0.22

1.36 (0.95–1.94)

0.09

1.25 (1–1.56)

0.046

Type of donor

MSD

1

 

1

 

1

 

1

 

1

 

UD

1.61 (1.27–2.04)

<0.001

1.52 (1.22–1.9)

<0.001

1.16 (0.87–1.55)

0.32

2.17 (1.52–3.09)

<0.001

1.25 (1.03–1.53)

0.03

CMV donor

Neg.

1

 

1

 

1

 

1

 

1

 

Pos.

1.04 (0.84–1.3)

0.69

1.08 (0.88–1.33)

0.46

1.12 (0.85–1.48)

0.43

1.06 (0.78–1.43)

0.73

1.06 (0.88–1.28)

0.51

CMV patient

Neg.

1

 

1

 

1

 

1

 

1

 

Pos.

1.12 (0.89–1.41)

0.34

1.04 (0.84–1.29)

0.71

0.97 (0.73–1.3)

0.84

1.1 (0.8–1.51)

0.57

1.02 (0.84–1.24)

0.82

In vivo T cell depletion

No

1

 

1

 

1

 

1

 

1

 

Yes

0.87 (0.59–1.27)

0.47

0.92 (0.65–1.31)

0.66

1.17 (0.72–1.9)

0.53

0.75 (0.44–1.28)

0.29

0.68 (0.51–0.92)

0.01

Cytogenetics

Intermediate

1

 

1

 

1

 

1

 

1

 

Poor

1.71 (1.39–2.1)

<0.001

1.79 (1.48–2.16)

<0.001

2.41 (1.87–3.1)

<0.001

1.28 (0.95–1.73)

0.1

1.57 (1.32–1.88)

<0.001

Secondary AML

No

1

 

1

 

1

 

1

 

1

 

Yes

1.21 (0.93–1.56)

0.15

1.22 (0.96–1.56)

0.1

0.88 (0.61–1.29)

0.52

1.58 (1.14–2.18)

0.005

1.2 (0.96–1.49)

0.1

KPS

≥90

1

 

1

 

1

 

1

 

1

 

<90

1.43 (1.13–1.79)

0.002

1.41 (1.16–1.72)

<0.001

1.27 (0.96–1.68)

0.09

1.67 (1.22–2.29)

<0.001

1.38 (1.15–1.65)

<0.001

  1. Center effect or “frailty” was taken into account. Year of allo-HCT was included as integer and not as continuous variable. The HR of year of allo-HCT was calculated corresponding to an increase of 3 years. Patients were censored at 2 years of follow up.
  2. FluMel fludarabine/melphalan, FBM fludarabine/BCNU/melphalan, FTM fludarabine/thiotepa/melphalan, LFS leukemia-free survival, OS overall survival, RI relapse incidence, NRM non-relapse mortality, GRFS GvHD-/relapse-free survival, HR hazard ratio, CI confidence interval, AML acute myeloid leukemia, CR complete remission, MSD matched sibling donor, UD unrelated donor, KPS Karnofsky performance status, Pat. patient, Don. donor, CMV cytomegalovirus, CR complete remission, neg. negative, pos. positive, NA not assessed.
Back to article page